

### Personal Information



## Zeba Aziz

**Address:** Hameed Latif Hospital, Pakistan

**Country:** Pakistan

### Curriculum Vitae

#### POSITIONS HELD

- **Nov 2013 - Present**  
Professor, Head of Hematology & Oncology Department, Hameed Latif Hospital, Lahore, Pakistan
- **August 1998 – October 2013**  
Professor of Oncology/Hematology, Allama Iqbal Medical College, Lahore, Pakistan
- **August 1993 - August 1998**  
Associate Professor Hematology/Oncology, Allama Iqbal Medical College, Lahore, Pakistan.
- **December 1990 - December 1992**  
Medical Advisor in Pakistan - Shaukat Khanum Memorial Hospital and Cancer Research Center.
- **March 1988 - August 1993**  
Consultant Hematologist/Oncologist, Sheikh Zayed Hospital and Federal Postgraduate Medical Institute, Lahore, Pakistan.  
In charge of the Oncology Department at Sheikh Zayed Hospital and Federal Postgraduate Medical Institute, Lahore.
- **March 1988 - September 1989**  
Incharge Hematology Laboratory at Sheikh Zayed Hospital and Federal Postgraduate Medical Institute, Lahore, Pakistan.
- **November 1987 - March 1988**  
Assistant Professor of Medicine Fatima Jinnah Medical College & Consultant Hematologist/Oncologist, Sir Ganga Ram Hospital, Lahore
- **June 1985 - August 1987**
  - a. Attending Physician at Yale University Health Plan, New Haven, CT., U.S.A.
  - b. Attending Physician at Queen's General Hospital, New York, Emergency Medicine Department.
  - c. Attending Physician at Meriden-Wallingford Hospital, Emergency Medicine Department.

#### Member

1. WHO expert panel of essential medicines 2017.
2. WHO essential medicine list working group 2014.

3. ACORD: Member Steering committee and Faculty member ACORD (Australia & Asia Pacific Clinical Oncology Research development Workshop).

4. DEAN: Medical Oncology: College of Physicians & surgeons.

### Professional Training

- January 11th 2014 – 30th January 2014  
Clinical Observership Program on MDS and NHL in NewYork-Presbyterian Hospital The University Hospital ofColumbia and Cornell.
- August 6th 2012 - 21st August 2012  
Emerging Regions Support and Partnership Program (iCMLF) OHSU Knight Cancer Institute S.W. Sam Jackson Park Road Portland.
- January 1977 - July 1981  
Residency in Internal Medicine St. Vincent's Medical Center Staten Island, New York.
- July 1981 - February 1982  
Hematology and Oncology fellowship Island Jewish Medical Center & Queens General Hospital, New York.
- July 1982 - June 1985  
Fellowship in Hematology/Oncology: Down State Medical Center, New York.

### Professional Qualification

- 1985  
Passed the American Board of Internal Medicine's examination in the Subspecialty of Oncology
- 1984  
Passed the American Board of Internal Medicine's examination in the Subspecialty of Hematology
- 1981  
Passed the Board of the American Board of Internal Medicine
- 1979  
Passed the FLEX Examination
- 1977  
Passed the Educational Commission for Foreign Medical Graduates Examination
- 1976  
M.B.B.S., Fatima Jinnah Medical College, Top 5% of class

### Abstracts and Publications

- 1) HLA-DRB1\*07:01 biomarker characterization of hepatotoxicity during lapatinib combination therapies in ALTTO
- 2) Effectiveness of targeted therapy in patients with previously untreated metastatic Breast Cancer: A systematic review and meta-analysis (Clinical Breast Cancer), Vol 15, Issue 2, April 2015, 90-100
- 3) Pregnancy outcomes in patients with chronic myeloid leukemia treated with imatinib mesylate: short report from a developing country. (Leukemia & lymphoma (Nov 2013) doi: 10.3109/10428194.2013.866662

- 4) Assessment of Quality of Life with Imatinib Mesylate as First Line Treatment in chronic Phase Chronic Myeloid Leukemia (Leukemia and Lymphoma), June 2011; 52(6): 1017–1023
- 5) Sustained Superior long Term Outcomes and cytogenetic responses with Imatinib Mesylate in Chronic Phase chronic Myeloid Leukemia: A report from a Developing Country. Aziz Z, Iqbal J, Banu K, Faisal M, Akram M. *Jpn. J. Clin. Oncol.* 2010; 40(6): 549 - 555.
- 6) Quality-of-life and quality-adjusted survival (Q-TWiST) in patients receiving Lapatinib in combination with paclitaxel as first-line treatment for metastatic breast cancer. *Clinical Medical Research and Opinion.* 2010. Vol. 26; 4:767-775.
- 7) The prevalence of germ-line TP-53 mutations in women diagnosed with breast cancer before age 30. *Familial Cancer* 2009. 8 (4); 563-567.
- 8) Worsened oncologic outcomes for women of lower socio-economic status (SES) treated for locally advanced breast cancer (LABC) in Pakistan. *Breast*; 2010.19: pp. 38-43.
- 9) Phase III trial of Casopitant, a Novel Neurokinin-1 Receptor Antagonist, for the Prevention of Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy. *JCO.* Vol27;32: 2009.5363-5369.
- 10) Casopitant, a Novel Neurokinin-1 Receptor Antagonist, for the Prevention of Chemotherapy-Induced Nausea and Vomiting: Phase III Trial Results in Patients Receiving Moderately Emetogenic Chemotherapy. *Lancet* 2009. Vol.10:549-558.
- 11) Short Commentary: The Need for an Effective Palliative Care Strategy in Pakistan. *Journal of Public Health Policy.* Vol (29); 4: 480-484 (10 Dec 2008).
- 12) Phase III results for the novel neurokinin-1 (NK-1) receptor antagonist, casopitant: 3-day IV/oral dosing regimen for chemotherapy-induced nausea and vomiting (CINV) in patients (Pts) receiving moderately emetogenic chemotherapy (MEC). Abstract: 20512. ASCO 2008.
- 13) Phase III results for the novel neurokinin-1 (NK-1) receptor antagonist, casopitant: Single oral dosing regimen for chemotherapy-induced nausea and vomiting (CINV) in patients (pts) receiving highly emetogenic chemotherapy (HEC). Abstract: 20585. ASCO 2008
- 14) Phase III, Double-Blind, Randomized Study Comparing Lapatinib plus Paclitaxel with Placebo plus Paclitaxel as First-Line Treatment for Metastatic Breast Cancer. *JCO* Dec 1 2008: 5544–5552.
- 15) Frequency of CHEK2 1100delC Mutation among Women with Breast Cancer: An International Study. *Cancer Research* 2008; 68 :(7). April 1, 2008.
- 16) Novel Treatment Approaches for Managing Early-Stage Breast Cancer- Maximizing Safety and Outcome with adjuvant Taxane-containing Chemotherapy Regimens-a report. *Asia-Pacific Oncology & Hematology.* Vol. 1:27-30.2008.
- 17) Across generations: Cancer treatment in developing countries. *JCO* Oct 20 2008: 4990–4991
- 18) Effect of social class disparities on presentation and survival in breast cancer patients from developing countries. *The Breast Journal*, Volume 14 Number 4, 2008: 372–375.
- 19) HER2-Negative or Unknown Metastatic Breast Cancer. Richard S. Finn, Michael F. Press, Judy Dering, Henry Gomez, Zeba Aziz, Michael Arbushites, Maria Koehler, Cristina Oliva, Lisa S. Williams, Angelo Di Leo. (accepted for publication).
- 20) Predictive and Prognostic Factors Associated with Survival Outcomes in Patients with Stage I-III Breast Cancer: A Report from a Developing Country. *Asia-Pacific Journal of Clinical Oncology* 2008; 4: 81-90
- 21) Lapatinib (Tykerb) (L) with paclitaxel versus paclitaxel as first-line treatment for patients with metastatic breast cancer: a Phase III randomized double-blind study of 580 patients. A. DiLeo, H. Gomez, Z. Aziz, Z. Zvirbule, M. Abrushites, M. Koehler, L. Williams, J. Dering, RS. Finn. ASCO 2007.
- 22) Efficacy and Safety of Lapatinib as First-line Therapy for ErbB2-Amplified Locally Advanced or Metastatic Breast Cancer. *JCO.*2008, Vol.28(18): 2999-3005.
- 23) Treatment of Chronic Myeloid Leukemia in the Imatinib Era: Perspective from a Developing Country. Aziz Z, Iqbal J, Akram M, Saeed S. *Cancer* 2007;(109)6:1138-1145

- 24) Principles and Practice of Cancer Screening in South Asian Context. R Sankaranarayanan, K Ramadas, Ashrafunnessa, Z Aziz, A Shah, S Thara, M.A. Yasantha Aryaratne. For UICC Handbook, 2006.
- 25) Brief Continuing Medical Education (CME) Module Raises Knowledge of Developing Country Physicians. International Electronic Journal of Health Education, 2006. (9):p31-41.
- 26) Treatment and Allocation of Resources Panel. RW Carlson, Z Aziz, J Bines, GN Hortobagyi, NS Besse, RR Love, B Vikram, A Kukure and BO Anderson for the Global Summit The Breast Journal, Vol. 12, Suppl.1, 2006, S 38-S53.
- 27) Breast Cancer in Limited-Resource Countries: Treatment and Allocation of Resources. A Eniu, RW Carlson, Z Aziz, J Bines, GN Hortobagyi, NS Besse, RR Love, B Vikram, A Kukure and BO Anderson for the Global Summit Treatment and Allocation of Resources Panel. The Breast Journal. Vol. 12, Suppl.1, 2006, S 38-S53
- 28) Report of an International Network of Cancer Treatment Research Workshop on Non-Hodgkin's Lymphoma in developing countries. Blood Cells, Molecules and Diseases 33 (2004), 330-337.
- 29) Socioeconomic status and Breast Cancer survival in Pakistani women. Z. Aziz, S. Sana, M. Akram, A. Saeed JPMA, September, 2004 Vol. 54 Page no. 448 – 453.
- 30) Institution Based Tumor Registry from Punjab: Five Year Data Based Analysis. Z. Aziz, S. Sana, S. Saeed, M. Akram. JPMA, 53:350; August 2003.
- 31) A Prospective Randomized Study of CHOP versus CHOP Plus Alpha-2B Interferon in Patients with Intermediate and High Grade Non-Hodgkin's Lymphoma: the International Oncology Study Group NHL1 Study. Leukemia and Lymphoma. 2000, Vol.40 (1-2), 95-103.
- 32) Prospective evaluation of efficacy and toxicity of 5FU and folinic acid (Mayo clinic regimen) in patients with advanced cancer of gall bladder. Am J Clin Oncol. 2003, 26:124-126.
- 33) Gemcitabine and Cisplatin: A highly effective combination chemotherapy in patients with advanced cancer of the gall bladder. Malik IA, Aziz Z, Zaidi SH, Sethuram G: Am J Clin Oncol. 2003, 26:174-177.
- 34) Clinico-pathological features and management of immunoproliferative small intestinal disease and primary small intestinal lymphoma in Pakistan. Malik IA, Shamsi Z, Shafquat A, Aziz Z, Shaikh H, Jafri W, Khan MA, Khan AH Med Pediatr Oncol. 1995, Nov; 25(5):400-6.
- 35) Contribution of mutations in BRCA1 and BRCA2 to Breast and Ovarian Cancer in Pakistan. American Journal of Human Genetics. 2002; 71:595-606.
- 36) Rates of consanguinity and BRCA mutations among breast and ovarian cancer patients in Pakistan. ASCO 2002, Abstract 1711, Vol. 21, page 428a
- 37) Applicability of International Prognostic Index in non-Hodgkin's Lymphoma in Pakistan PROCEEDINGS OF ASCO 2002 May Vol.21, Abstract 2641, Page No. 206b.
- 38) Hodgkin's Disease: Analysis of 75 Patients. M. Akram, MH Cheema, S. Sana, Z. Aziz. JCPSP Vol.11.No.11, 2001, 702-05.
- 39) Phase I Trial of Ifosfamide and Adriamycin in Metastatic Breast Cancer. Z. Aziz, S. Sana, M. Akram, Naseem Ilyas. JPMA. Vol. 51, No. 11, November, 2001.
- 40) Non-Hodgkins Lymphoma in Pakistan: A Clinico-pathological Profile of 175 Patients. Z. Aziz, A. Rehman, M. Akram, A. Saeed. JPMA. Jan 1999, Vol. 49, No.1, 11-15.
- 41) Ifosfamide and vinorelbine in metastatic breast cancer in patients with prior anthracycline therapy. Cancer Chemotherapy Pharmacology. 1999 Nov; 44 (7):S9-S12.
- 42) Malik I, Aziz Z. Clinico-pathological features and management of children with non-Hodgkin's lymphoma in Pakistan - a retrospective analysis. Intern J Pediatr Hem Oncol. 1995, 1:617-621.
- 43) Malik, I. Moid, Z. Aziz, S. Khan: A Randomized Comparison of Fluconazole with Amphotericin B as Empirical Anti-Fungal Agents in Cancer Patients with Prolonged Fever and Neutropenia. The American Journal of Medicine. December 1998, Vol. 105, 478-483. A Multicenter study of

recombinant human erythropoietin (epoetin) in the management of anemia in cancer patients receiving chemotherapy---M Pawlicki, J Jassem, P Bosze, C Lotan, GP Kurteva, M Siddiqui, PA Kosmidis, GA Rigatos, E Kansu, P Durkovic, Z Aziz, HL Idrissi, A Roth and G Coszma (on behalf of the study group from Eastern Europe, Middle East and Western Asia) *Anti Cancer Drugs* November 1997, Vol. 8, No. 10, pg 949-957.

44) Clinico-pathologic features and management of children with Non-Hodgkin's-Lymphoma in Pakistan: A retrospective analysis of 85 patients. *Pediatric Research* 1997. 41 (5): 760.

45) Modified BFM-Protocol for childhood acute lymphoblastic leukemia: A retrospective analysis. *Medical and Pediatric Oncology*, 1997. Vol. 28; pg 48-53.

46) Update on the International Oncology study group (IOSG) CML 1 study: Hydroxyurea plus Alpha 2B Interferon versus Ara-C plus Ifn for Ph+ chronic phase CML, F Rana, Zeba Aziz, M Saleem, KA Salim, BL Rapoport, I Supandiman, V oovalingam, M Fuerst, SW Lim, MM Franco, DA Kusuanco and FJ Giles, Second International Cancer Conference, October 1996, Lahore, Pakistan.

47) Update on the (IOSG) NHL 1 study: CHOP plus interferon induction and Ifn Maintenance vs CHOP induction alone in intermediate and high grade NHL, Zeba Aziz, I Kalim, J Raffat, AF Adnan, A Villalon, PP Bapsy, A Harryanto R, H Khalid, MM Franco, DA Kusuanco and FJ Goles, Second International Cancer Conference, October 1996, Lahore, Pakistan.

48) Update on the International Oncology study group (IOSG) CML 1 study: Hydroxyurea plus Alpha 2B Interferon versus Ara-C plus Ifn for Ph+ chronic phase CML, F Rana, Zeba Aziz, M Saleem, KA Salim, BL Rapoport, I Supandiman, V oovalingam, M Fuerst, SW Lim, MM Franco, DA Kusuanco and FJ Giles, Second International Cancer Conference, October 1996, Lahore, Pakistan.

49) Update on the (IOSG) NHL 1 study: CHOP plus interferon induction and Ifn Maintenance vs CHOP induction alone in intermediate and high grade NHL, Zeba Aziz, I Kalim, J Raffat, AF Adnan, A Villalon, PP Bapsy, A Harryanto R, H Khalid, MM Franco, DA Kusuanco and FJ Goles, Second International Cancer Conference, October 1996, Lahore, Pakistan.

50) Alpha 2B interferon in intermediate-(IG) and high grade NHL the (IOSG) NHL 1 study. FJ Giles, A Vilalon, PP Bapsy, B Chaimongkol, J Raafat, S Jootar, A Harryanto R, I Taratorn, TG Sagar, SW Kim, C Suh, F Esfahani, AP Schwarzer, A Muthalib, HS Song, C Suharti, BL Rapoport, A Lekhakula, PM Chen, V Kuchopillai, SY Kim, R Kumar, M R Haron, NR Wickham, T Intragumtomchai, T Kannan, SK Cheong, CW Voges, MA Coccia Portugal, D Tian, KB Lee, L Bellarmine, S Serdengecti, O Doyeun, BK Smruti, PM Shah, N Sotamaphan, V Jinarantana, Z. Aziz, W Prayoonwivat, A Lim, KW Leong, KS Lam, BS Ho, NB Chang, P Ruff, DA Kusuanco, MM Franco. 26th Congress of the International Society of Haematology, August 1996, Singapore.

51) Alpha 2B interferon in Ph+ chronic-phase CML the (IOSG) CML 1 study. FJ Giles, KA Salim, PM Shah, BL Rapoport, V Poovalingam, I Supandiman, P Tan, R Torres, M Gonzaga, LX Wang, V Kochupillai, YC Chen, GY Tee, Z Fahed, C Suharti, SH Advani, LL Heng, M Patel, S Chen, R Sumantri, SN Lee, K Omari, MZ Abdul Hadi, D Tian, BS Ho, N Ona, KY Kim, A Cavilez, PM Parikh, Z. Aziz, A Muthalib, WR Bezwoda, MY Kim, LS Fourie, M Saleem, H Januszewicz, M Wolf, SN Lee, NB Chang, A Wijono, SW Lim, MP Fuerst, DA Kusuanco, MM Franco. 26th Congress of the International Society of Haematology, August 1996, Singapore.

52) Initial characteristics of Ph positive chronic-phase CML: A comparison between Asian and German patients on the IOSG CML1 and the German CML study group protocol. F J Giles, I Supandiman, P Tan, R Torres, M Gonzaga, LX Wang, V Kochupillai, YC Chen, GY Tee, Z Fahed, C Suharto, Sh Advani, LL Heng, M Patel, S Chen, R Sumantri, SN Lee, Komari, MZ Abdul Haid, D Tian, BS Ho, N Ona, KY Kim, A Cavilez, PM Parikh, Zeba Aziz, A Muthalib, SW Lim, MP Fuerst, DA Kusuanco, MM Franco. 26th Congress of the International Society of Haematology, August 1996, Singapore.

- 53) A retrospective analysis of CHOP therapy in Intermediate and High grade Non-Hodgkin's Lymphoma. Journal of Egyptian National Cancer Institute 1995, Vol: 7 No.2 page 163-167.
- 54) Clinico-epidemiological Features of Adult Leukemia's in Pakistan. A. Khalid, M. Zahid, A. Rehman, Z. Ahmed, S. Qazi, Z. Aziz. Journal of Pakistan Medical Association Vol.47,4:97, 119 - 122.
- 55) Acute Lymphoblastic Leukemia of Childhood: A Retrospective Analysis of Clinico-epidemiological features. Journal of Pakistan Medical Association 1996, Vol:6 , No:7,147-149.
- 56) Breast Cancer: Is Aggressive Follow-Up Necessary? Z.Aziz Journal American Medical Association (Pakistan) 1994 Vol. 6 No. 8, 444-445.
- 57) A prospective randomized trial of Fluconazole (FLU) versus amphotericin B (AMPHO) as empirical anti-fungal therapy of neutropenic febrile patients. I. Malik, I. Moid, Z. Aziz. Annals of Oncology 1994 Vol. 5, Suppl.8. page 197.
- 58) Clinico-Pathologic features and Management of Children with Non Hodgkin's Lymphoma in Pakistan. Z. Aziz, I. Malik, International Journal of Pediatric Hematology/Oncology 1995, (6): 617-21.
- 59) Immunoproliferative small intestinal disease and primary small intestinal lymphoma: Is it expanding its geo-graphic confines? I. Malik, Z. Shamsi, Z. Aziz et al. (submitted).
- 60) Feasibility of out- patient management of fever in cancer patients with low risk neutropenia: Results of a prospective randomized trial -- I. Malik, W. Khan, M. Karim, Z. Aziz The American Journal of Medicine Vol-98 Page 224 - 231 March 1995
- 61) To Kill Two Birds with One Stone: Z. Aziz, I. Malik, JAMA Pakistan March 1994, Vol. 6, No. 1, 5-6.
- 62) Human Immunodeficiency Virus: Diagnostic Pitfalls and Management Issues -- I. Malik, Z. Aziz, JAMA Pakistan 1993: 5(9) 418-419.
- 63) Importance of Age in Determining Outcome after Allogeneic Bone Marrow Transplantation, Z. Aziz, I. Malik, JAMA, Pakistan 1993, Vol. 5(7), 255-356.
- 64) Multicenter trial of single agent versus combination chemotherapy in metastatic breast cancer, I. Malik. Z. Aziz, M. Shahid, G. Sarwar, N. Kizilbash, A. Rab Khan, A. Javed, S. Muhammad, G. Memon, M. Ilyas. PROCEEDINGS OF ASCO 1993, March. Vol. 12, Abstract 224, Page No. 106.
- 65) A randomized trial to evaluate the role of ofloxacin in the out-patient management of neutropenic febrile patients, I. A. Malik, M.D., Z. Aziz, M.D., W.A.Khan, M.D., ANNALS OF ONCOLOGY Volume 3, Supplement 5 Nov. 1992, Page No. 179, Abstract 686.
- 66) Management of early stage Prostate Cancer Recent developments and controversies -- Z. Aziz, I. Malik, JAMA Pakistan, July 1992, Vol. 4, No. 5, 230-231.
- 67) Paroxysmal Nocturnal Hemoglobin urea. Proceedings Sheikh Zayed Post Graduate Medical Institute. June, 1991.
- 68) Treatment of Metastatic Breast Cancer: How much is too much? JAMA Pakistan, August, 1992, Vol. 4, 280-281.
- 69) Non-A, Non-B, Non-C, Now what? Oh, Such a Tangled Web -- Z. Aziz, I. Malik. JAMA Pakistan, June 1992, Vol. 4, 175-176.
- 70) Clinical features of Non-Hodgking Lymphoma in Pakistan- Z. Aziz, A. Shafquat, and I. Malik. Abstract 1119. Page No. 328. PROCEEDINGS OF ASCO VOL. 11, March, 1992.
- 71) Immunoproliferative Small Intestinal Disease (IPSID) and small Intestinal Lymphoma, I. Malik, A. Shafquat, Z. Shamsi, Z. Aziz, M. Khurshid, J. Ismail, H. Sheikh, S. Syed, H. Khan and A. Khan. Abstract 887. Page No.269 PROCEEDINGS OF ASCO VOL. 11, March, 1992.
- 72) Clinical Features of Breast Cancer in Pakistan -- I. Malik, A. Vali Muhammad, Z. Aziz, F. Malik, G. Sarwar and M. Zaidi. Abstract 139 Page No. 78 PROCEEDINGS OF ASCO VOL. 11, March, 1992.

- 73) Hemangiopericytoma -A case of combined modality treatment Z. Aziz MD, M. Zahid MD, S.Qazi MD, H Zaman, European Journal of Surgical Oncology 459-461,October, 1997
- 74) Self administered antibiotic therapy of febrile episodes in cancer patients with chemotherapy induced neutropenia. Malik I, Khan A, Aziz Z. Clinical Infectious Diseases Page 522 - 527 19 September 1994.
- 75) Phase II trial of Ifosfamide and Cisplatin in Advanced Ovarian Cancer. Z.Aziz MD, M.Zahid, Zaheeruddin, T.Arshad. Current Developments and Future Directions in Oncology Supplement, Australian and New Zealand Journal of Medicine.28; 403-409,1998.
- 76) Bone Marrow Aspiration and Biopsy at Sheikh Zayed Hospital, Lahore. Proceedings Sheikh Zayed Post Graduate Medical Institute Vol. 4, 1990.
- 77) Hematological Malignancies (Editorial) Pakistan Journal of Medical Research Vol. 28, No.4, 1989.
- 78) Preliminary Report on a small group of patients with advanced Hodgkin's disease. Pakistan Journal of Medical Research Vol. 28, No.2, 1989.
- 79) Bone marrow Transplant in Leukemia's, Pakistan Journal of Medical Research Vol. 28, No.1, 1989.
- 80) Unwilling Heparin Abuse in a Drug Addict, Annals of Internal Medicine Vol. 96, No. 6 June, 1982.

### Oral Presentation

1. INVITED SPEAKER:12<sup>th</sup> Shaukat Khanum Hospital Symposium (Fighting cancer on all fronts) Nov 29<sup>th</sup> to Dec 1, 2013.
2. INVITED SPEAKER: Academy of CML experts (ACE) in Mumbai, India on 28<sup>th</sup> – 29<sup>th</sup> July 2012.
3. INVITED SPEAKER: International Network of Cancer Treatment & Control (INCTR). (Antalaya, Turkey) March 2009.
  - (a) Economics challenges in management of colon cancer in LMC'
  - (b) Preliminary Results of INCTR Survey of Breast Cancer Therapy in Four Countries.
  - (c) CO-CHAIR: Adult cancers: Proffered papers
4. INVITED SPEAKER: INCTR SYMPOSIUM: Breast cancer in Asia: Current scenario. Bangkok November 15<sup>th</sup>-17<sup>th</sup> 2007
5. INVITED SPEAKER: International Network of Cancer Treatment & Control (INCTR) (San Paolo). Use of Complementary Medicines in Cancer Patients from Developing Countries. March 2007. INVITED FACULTY: AACR Workshop on Research Methodology in Translational Research. (A) PANEL CHAIR: What is a good research idea? Singapore, November 2-3, 2007
6. INVITED FACULTY: Australia and Asia Clinical Oncology Research Development Workshop (ACORD). August 2006.
  - (a) Chair panel: Research across the World.
  - (b) Co-presenter with Professor Ian Tannock: Critical Appraisal of Literature & Clinical Presentation Skills. Skills
7. INVITED SPEAKER: International Network of Cancer Treatment & Control (INCTR). Importance of clinical trials in breast cancer in developing countries. December 2005, Chennai, India.
8. INVITED SPEAKER: Shaukat Khanum Memorial Trust Hospital.6<sup>th</sup> Cancer Symposium: Overview of Breast Cancer in Developing Countries. March 2005, Lahore, Pakistan.
9. INVITED SPEAKER: 3<sup>RD</sup> Conference of the Federation of Oncologists from SAARC Countries: Expanding Borders in Oncology: Breast Cancer in SAARC Countries. April, 2005, Goa, India.
10. INVITED SPEAKER: International Network of Cancer Treatment & Control (INCTR). Breast Cancer Strategy group Report. October 2004, Cairo, Egypt.

11. INVITED SPEAKER: International Cancer Congress-2004: Fertility Issues in Breast Cancer after Treatment. September 2004, New Delhi, India.
12. INVITED FACULTY: Industry versus Academia Panel member. Australia and Asia Clinical Oncology Research Development Workshop (ACORD). August 2004.
13. INVITED SPEAKER: International Cancer Congress-2004: Fertility Issues in Breast Cancer after Treatment. September 2004, New Delhi, India.
14. INVITED SPEAKER: RGCON 3. Role of Chemotherapy in Advanced Gall bladder Cancer. April 2004, New Delhi, India.
15. INVITED SPEAKER: 5<sup>th</sup> National Urological Conference: Evolving Role of Chemotherapy in transitional Cell Bladder Cancer. Lahore, March 6-7, 2004.
16. INVITED SPEAKER at Medical Research Society of Pakistan. New Frontiers & Challenges in the Management of Chronic Myeloid Leukemia (CML). Lahore. December 20, 2003.
17. INVITED SPEAKER at SKMT meeting. Breast Cancer in Pakistan with emphasis on Hereditary Breast Cancer and Socioeconomic Status. Dubai. October 4-5, 2003
18. INVITED SPEAKER at Pakistan Society of Clinical Oncology. Medical management of DCIS. December, 20-22, 2002.
19. INVITED SPEAKER at INCTR Meeting: Treatment of Breast Cancer in Pakistan. Brussels, May 29-1, 2002.

### Poster Presentation

- 1) Neutropenia and hematologic sequelae in patients receiving Casopitant-containing antiemetic therapy for cisplatin based highly Emetogenic chemotherapy. Abstract: 3022. ECCO 2009.
- 2) Phase III results for the novel neurokinin-1 (NK-1) receptor antagonist, casopitant: Single oral dosing regimen for chemotherapy-induced nausea and vomiting (CINV) in patients (pts) receiving highly emetogenic chemotherapy (HEC). Abstract: 9549. ASCO 2008.
- 3) Phase III results of a novel oral neurokinin-1 (NK-1) receptor antagonist, casopitant: Single oral dosing regimens for chemotherapy-induced nausea and vomiting (CINV) in patients (pts) receiving moderately emetogenic chemotherapy (MEC). Abstract: 9540. ASCO 2008.
- 4) Survival outcomes in locally advanced breast cancer (LABC): A report from a developing country. —The 2007 Breast Cancer Symposium: Emerging Science into Clinical Practice” (in San Francisco September 2007).
- 5) Epidemiology and survival in colorectal cancer: a retrospective analysis from a developing country. World Gastrointestinal Cancer Congress (WGIC). Barcelona, June 2007.
- 6) Unraveling Pharmacogenomic basis of Primary Imatinib Resistance. Z Iqbal, RT. Siddiqui, JA. Qureshi and ZAziz. International Conference on Tumor Progression and Therapeutic Resistance. November 8-9, 2004, Philadelphia.
- 7) Socioeconomic Status and Breast Cancer Survival in Pakistani Women. ESMO, Nice, October 2002. (Was selected for press conference)
- 8) Contribution of mutations in BRCA 1 & BRCA 2 and Consanguinity to Breast and Ovarian Cancer in Pakistan. ASCO May 2002.
- 9) Mitomycin C, ifosfamide, cisplatin (MIC) in patients with advanced of recurrent cervical cancer.
- 10) Prevalence of anxiety and depression in cancer patients receiving chemotherapy ESMO, Greece November 1998.
- 11) Ifosfamide and cisplatin, followed by intraperitoneal carboplatin and etoposide in advanced ovarian cancer. ESMO, Vienna, Austria -1996.
- 12) Epidemiologic features of Breast Cancer in Pakistan - 10th Asia Pacific Cancer Conference, Beijing, China - 1991.
- 13) Clinico-epidemiologic features of Non-Hodgkin Lymphomas - 10th Asia Pacific Cancer Conference. Beijing, China - 1991.



## Professional Activities, Presentation and meeting

1. INVITED SPEAKER: International Network of Cancer Treatment & Control (INCTR). Role of Complementary Medicines in Cancer in South Asia. San Paolo, Brazil. February 2007.
2. INVITED FACULTY: Australia and Asia Clinical Oncology Research Development Workshop (ACORD). August 2006.
3. INVITED SPEAKER: International Network of Cancer Treatment & Control (INCTR). Importance of clinical trials in breast cancer in developing countries. December 2005, Chennai, India.
4. INVITED SPEAKER: Shaukat Khanum Memorial Trust Hospital. 6<sup>th</sup> Cancer Symposium: Overview of Breast Cancer in Developing Countries. March 2005, Lahore, Pakistan.
5. INVITED SPEAKER 3<sup>RD</sup> Conference of the Federation of Oncologists from SAARC Countries: Expanding Borders in Oncology: Breast Cancer in SAARC Countries. April, 2005, Goa, India.
6. INVITED SPEAKER: International Network of Cancer Treatment & Control (INCTR). Breast Cancer Strategy group Report. October 2004, Cairo, Egypt.
7. INVITED SPEAKER: International Cancer Congress-2004: Fertility Issues in Breast Cancer after Treatment
8. INVITED SPEAKER: RGCON 3. Role of Chemotherapy in Advanced Gall bladder Cancer. April 2004, New Delhi, India.
9. INVITED SPEAKER: 5<sup>th</sup> National Urological Conference: Evolving Role of Chemotherapy in transitional Cell Bladder Cancer. Lahore, March 6-7, 2004.
10. INVITED SPEAKER : Medical Research Society of Pakistan. New Frontiers & Challenges in the Management of Chronic Myeloid Leukemia (CML). Lahore. December 20, 2003.
11. INVITED SPEAKER at SKMT meeting. Breast Cancer in Pakistan with emphasis on Hereditary Breast Cancer and Socioeconomic Status. Dubai. October 4-5, 2003
12. INVITED SPEAKER at Pakistan Society of Clinical Oncology. Medical management of DCIS. December, 20-22, 2002.
13. INVITED SPEAKER at INCTR Meeting: Treatment of Breast Cancer in Pakistan. Brussels, May 29-1, 2002.
14. INVITED SPEAKER at AGA KHAN UNIVERSITY HOSPITAL conference —Non-Hodgkin's Lymphoma in developing countries|| September 17-18 Karachi Pakistan.
15. INVITED SPEAKER: Fifth Shaukat Khanum Memorial Cancer Symposium —Institutional based Tumor Registry||. Feb 17-20, 2001.
16. INVITED SPEAKER: Fifth Shaukat Khanum Memorial Cancer Symposium —Clinicopathological aspects of Breast Cancer in Pakistan||. Feb 17-20, 2001.
17. INVITED SPEAKER Satellite Symposium of New Options for Palliative Treatment of Breast Cancer —Ifosfamide and Vinorelbine in Metastatic Breast Cancer in Patients with Prior Anthracycline Therapy" 1st European Breast Cancer Conference Sep 29- Oct 3, 1998 - Florence, Italy.
18. INVITED SPEAKER on Symposium of —Gynecologic Oncology|| Chemotherapy considerations in advanced ovarian cancers. November 8-9, 1997 Institute Rotary Cancer Centre, All India Institute of Medical Sciences, New Delhi, India.
19. 17th Asia Pacific Cancer Conference Hong Kong, November 1997, —Ifosfamide and vinorelbine in metastatic breast cancer in patients with prior anthracycline therapy||.
20. IAEA\_PAEC International Workshop on Nuclear Medicine and Radiotherapy, March 1997, Phase II Trial of Ifosfamide and cisplatin in advanced Ovarian Cancer.
21. INVITED SPEAKER: Managing Gender Diversity. Lahore University of Management Sciences, March 1997.
22. INVITED SPEAKER : 17th International Conference Medical and Health Conference, Dec. 1996, Multan —Clinical features of Non- Hodgkin's Lymphomas in Pakistan||.

23. PANELIST: Third International Radiological Conference, Dec 1995. —Organizing Cancer Treatment Services||.
24. INVITED SPEAKER: Pakistan Islamic Medical Association, Dec 1995."Anemias".
25. INVITED SPEAKER: Society of Surgeons Pakistan, Faisalabad chapter, "What's new in Breast Cancer".
26. INVITED SPEAKER :Fifth All-Pakistan Biennial Cancer Conference, Lahore, Oct 1995. "Chemoprevention in Breast Cancer".
27. INVITED SPEAKER: Second International Course in Advanced Hematology, AFIP Rawalpindi. November, 1995."Interferons in Cancer".
28. European Society for Pediatric Hematology and Immunology 15th Scientific Congress in Bingen, August 1995."Modified BFM protocol for childhood acute lymphoblastic leukemia: A retrospective analysis".
29. INVITED SPEAKER: First International Course in Advanced Hematology, AFIP, Rawalpindi. November, 1994. Growth factors - Basic Biology. Therapeutic use of Growth Factors.
30. INVITED SPEAKER: Women in Management Program. Lahore University of Management Sciences & Mc Gill University May 1994 - Local Resource Person.  
Token Woman in Medical Profession - Case Discussion.  
The Balancing act. -- Panel Discussion.
31. International Post Graduate Workshop on "Management of Malignant Disorders" April, 1994 in Karachi. "Role of Chemotherapy in Ovarian Cancer".
32. Cancer Chemotherapy Symposium - Radiological Society of Pakistan and PCOG 3rd International Oncology Conference, December 1993 in Peshawar, "Supportive Care in Cancer Chemotherapy".
33. Congress 1993 - College of Physicians and Surgeons Pakistan with Bangladesh College of Physicians and Surgeons and International College of Surgeons, Karachi, December 1993 - "Management of Side Effects of Chemotherapy".
34. 11th Asia Pacific Cancer Conference Bangkok, Thai-land - November 1993,"The Effect of Subcutaneous Recombinant Erythropoietin on Anemia in Cancer Patients receiving Cisplatin or Carboplatin.
35. 11th Asia Pacific Cancer Conference Bangkok, Thailand - November 1993, "A Phase II Study of Ifosfomide and Cisplatin in previously untreated patients with stage III & IV Ovarian Cancer"
36. Fourth Biennial International Surgical Conference Lahore - February 17, 18 1993. "Is Cancer Curable"
37. Twentieth Biennial Conference of Pakistan Medical Association, December 1992, Karachi. "Recent Advances in Cancer Management".
38. Second International Oncology Conference Karachi, November, 1992 "Management of Ovarian Cancer".
39. XII International Biennial Paediatric Conference held in February, 1992. "NHL - A Clinico Pathological Study of 30 cases".
40. Fifth Annual Intensive Postgraduate Course in Obstetrics & GYNECOLOGY, Allama Iqbal Medical College, Lahore - February, 1992.  
Ovarian Cancers.  
Anemias in Pregnancy
41. College of General Practitioners Pakistan Lecture on Cancer "New Diagnosis and Treatment Modalities" February, 1992.
42. First International Oncology Conference held by Pakistan Co-operative Oncology Group in College of Physicians and Surgeons, Karachi November, 1991. Papers read:-  
Management of Ovarian Cancer.  
Clinico-epidemiological study in Non-Hodgkin's Lymphoma.

43. 2nd National Seminar on Recent Advances in Medical Science held by Pakistan Medical Association in Lahore, November, 1991. Lecture on "Bone Marrow Transplant and Growth Factors".
44. First Annual Consensus Conference on Treatment of Breast Cancer held by Radiology Society August, 1991 -- "Role of Chemotherapy in Early Stage Breast Cancer".
45. Hematology Lectures FCPS Part-I review course held twice a year. 1989, 1990, 1991.
46. Fifth Annual Pediatric Conference of Pakistan Pediatric Association June, 1991 "Experience of Childhood Leukemia's Protocol and Comparison of UKALL 10 with BFM Protocol.
47. Ninth Asia Pacific Cancer Conference November, 1989 -- "Preliminary report on a small group of patients with advanced Hodgkin's disease with Adriamycin VP16, Bleomycin, Prednisolone and Vincristine.
48. WHO working group for National Cancer Control in Pakistan December 1990 -- "Diet Contamination and Carcinogenesis in Pakistan".
49. Third Annual Intensive Post Graduate Course held by "Department of Obstetrics and GYNECOLOGY, Allama Iqbal Medical College, Lahore" 1990.  
Role of Chemotherapy in Ovarian Cancer  
Role of Chemotherapy in Gestational Trophoblastic Tumors & Other Cancers.
50. Second annual Intensive Post Graduate Course held by Department of Obstetrics and GYNAECOLOGY "Chemo-therapy in Ovarian Cancers" 1989.
51. Intensive Review Course in Internal Medicine in Sheikh Zayed Hospital and Federal Post Graduate Medical Institute. Lecture on "Anemia, Lymphomas Leukemia's and Coagulation".
52. Sir John Hadfield Intensive Review Course in Surgery 1989 held in Sheikh Zayed Hospital and Federal Post Graduate Medical Institute. Lecture on "Diagnosis and Management of Metastatic Carcinoma.
53. Symposium on "Hematologic Malignancies" held in Sheikh Zayed Hospital and Federal Post Graduate Medical Institute in 1990. Lecture on "Hodgkin's disease and Non Hodgkin's Lymphoma in children".
54. Symposium on "Ovarian Cancer" held in Sheikh Zayed Hospital and Federal Post Graduate Medical Institute 1989 Lecture on "Role of Chemotherapy in Ovarian Cancer".

### **Current Research Activities**

1. A Randomized Double-Blind, Placebo-Controlled, Multicenter, Phase III Study Comparing GW572016 and Letrozole versus Letrozole in Subjects with Estrogen Progesterone Receptor Positive Advanced or Metastatic Breast Cancer.
2. A Double-blind, Placebo-controlled, Mutlicentric Phase IIb Extension Study to Evaluate the Safety and efficacy of Multiple Alvimopam Dosage Regimens for the Treatment of Opioid Induced Bowel Dysfunction in Cancer Pain Subjects.
3. EXTEND (Eltrmbopag eXTENDED Dosing Study): An extension study of eltrombopag Olamine (SB-4971-GR) in adults, with idiopathic thrombocytopenic purpura (ITP), previously enrolled in an eltrombopag study

### **Research Activities (In House)**

1. A Phase II study of primary systemic therapy (doxorubicin, taxotere and CMF) in Her 2 neu negative locally advanced breast cancer.
2. Low dose —Metronomic|| chemotherapy in metastatic breast cancer.
3. Outcome of Metastatic Breast Cancer in Developing Countries—an Audit of 235 Cases

## College of Physicians and Surgeons Pakistan

August 1994 to present

- **Member, Faculty of Medical Oncology.**
- **FCPS Examiner for Medical Oncology.**
- **Supervisor, Medical Oncology, FCPS**
- **Convener Medical Oncology, FCPS.**

## Supervisors

### **For FCPS Part-II Dissertation for Internal Medicine:**

1. Non Hodgkin's Lymphoma in Pakistan: A clinico-pathological study.

### **Co-supervisor M. Phil Pharmacy.**

2. Acute toxicities of Alkylating agents and Anti-metabolites.

### **For FCPS Part-II Dissertation for Medical Oncology:**

- 3) Low dose erythropoietin in anemia of cancer patients.
- 4) Family history of cancer in breast cancer patients.
- 5) Clinico- pathologic features and survival in ovarian cancer in Pakistan.
- 6) Clinico-pathological features and survival in Hodgkin's Disease in Pakistan.
- 7) Evaluation of the effect of early intervention and/or treatment with e-protein alfa on anemia in cancer patients receiving platinum based chemotherapy.

## Convenors

- First International Pediatric Oncology Conference November 1994.
- Second International Cancer Conference October 1996.
- Third International Cancer Conference October 1998.

## Memberships

1. American Society of Clinical Oncology.
2. Pakistan Oncology Cooperative Group.
3. Pakistan Medical Association.
4. Asian Clinical Oncology Society \_COUNCIL MEMBER.
5. Multinational Association of Supportive Care in Cancer.
6. European Society of Pediatric Hematology & Immunology.
7. European Society of Medical Oncology.
8. American Society of Hematology.
9. Member International Network for Cancer Treatment & Research-INCTR.(Strategy group member for breast cancer and NHL)
10. Member S.I.S. Scientific Centers Network.
11. Member Editorial Board of Update in Cancer Therapy
12. Member Steering committee and Faculty member ACORD (Australia & Asia Pacific Clinical Oncology Research development Workshop).